Most GLP-1 receptor agonists are administered subcutaneously once weekly (semaglutide, dulaglutide, tirzepatide) or once daily (liraglutide), though frequency varies by specific medication
Clark, R G, and I C Robinson
GLP-1 receptor agonists are well known to cause gastrointestinal symptoms, including abdominal pain, diarrhea, and vomiting
It does note that more research studies are needed before definitive recommendations can be made
Tables 2, 3, 4 and 5 summarize the main preclinical and clinical studies on the effects of DPP-4 inhibitors on bone metabolism
A noticeable enrichment in the number of TMA-producing subcommunities was observed, but again no individual isolate could perform the l-carnitineTMA transformation